Takeda Pharm Stock Price, News & Analysis

LIVTENCITY is now the first and only treatment for cytomegalovirus (CMV) infection approved by the European Commission (EC) for patients with post-transplant infections. CMV is a prevalent issue post-transplant, affecting 16-56% of solid organ transplant patients. The approval is based on the successful results of the Phase 3 SOLSTICE trial. LIVTENCITY targets the UL97 protein kinase, offering a novel option where previous therapies failed, enabling healthcare providers across the EU and EEA to manage refractory CMV cases effectively.

Takeda reported strong financial results for the first half of fiscal year 2022, with core revenue growth of 5.5% at constant exchange rates (CER) and reported revenue growth of 10.1%. Core operating profit grew 14.5% at CER, achieving a core operating profit margin of 31.7%. The company upgraded its peak sales outlook for ENTYVIO® to $7.5-9.0 billion and improved net debt to adjusted EBITDA to 2.6x. Takeda also reaffirmed its full-year guidance, reflecting strong performance in key business areas and ongoing product approvals.

Takeda has entered into a collaboration with Zedira and Dr. Falk Pharma to exclusively develop and commercialize TAK-227 (ZED1227) for celiac disease in the U.S. and other regions outside of Europe, Canada, Australia, and China. This investigational oral therapy aims to inhibit the immune response to gluten, addressing a significant unmet need in celiac disease treatment. The agreement adds a promising candidate to Takeda's pipeline, which already includes two other investigational therapies for celiac disease, both recently entering Phase 2 trials.

Takeda announced a positive opinion from the European Medicines Agency's CHMP for its dengue vaccine candidate, TAK-003. This recommendation supports the vaccine's use in individuals aged four and older across Europe and dengue-endemic countries. The decision is based on over 4.5 years of safety and efficacy data from a pivotal Phase 3 trial involving more than 20,000 participants. Marketing authorization in Europe is anticipated soon, with further regulatory reviews expected in Latin America and Asia.

Takeda has announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in pediatric patients aged 2 to <12 years old. Currently, no approved prophylactic treatments exist for children under 6. If approved, TAKHZYRO would be the first treatment available for this demographic. The FDA has granted priority review, with a decision expected in the first half of 2023.

Takeda and UNITAR have launched a joint initiative to enhance healthcare systems for plasma and plasma-derived therapies. This partnership aims to address the rising global demand for these therapies due to increasing patients with rare diseases. The initiative seeks to create a UN-based platform to unite experts, policymakers, and stakeholders, improving access and quality of life for patients. Takeda will contribute its expertise and funding, working collaboratively with countries to develop solutions tailored to their healthcare challenges.

Takeda and Enel North America have signed a 12-year virtual power purchase agreement (VPPA) to advance Takeda's sustainability goals. The agreement is expected to generate approximately 350,000 Megawatt Hours (MWh) of renewable energy credits annually, covering around 20% of Takeda’s current Scope 1 and 2 GHG emissions. The VPPA facilitates the purchase of electricity from Enel’s 79 MW Seven Cowboy wind project in Oklahoma, ensuring a sustainable energy source for Takeda’s U.S. facilities. This aligns with Takeda's target to reduce GHG emissions by 40% by 2025 and achieve net-zero emissions by 2035.

Takeda announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for maribavir, a treatment for cytomegalovirus (CMV) in adults post-transplant. This would be the first CMV-specific UL97 protein kinase inhibitor in the EU. The recommendation stems from the Phase 3 SOLSTICE study, which showed maribavir's superiority over conventional therapies at week 8. CMV affects 16%-70% of transplant recipients, necessitating effective treatment options.

Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.